Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raghavan Chinnadurai

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Advances in Experimental Medicine and Biology|May 31, 2023
Advanced Technologies for Potency Assay MeasurementRaghavan Chinnadurai
Hepatology (Baltimore, Md.)|November 11, 2010
B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cellsRaghavan Chinnadurai, Arash Grakoui
Stem Cells (Dayton, Ohio)|October 29, 2025
Opportunities with artificial intelligence in assessing the potency of mesenchymal stromal cellsRaghavan Chinnadurai, Anant Madabhushi
Frontiers in Immunology|May 8, 2023
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysisRaghavan Chinnadurai, Sowmya Viswanathan, Guido Moll
AIDS (London, England)|August 17, 2005
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Frank Kirchhoff
World Journal of Gastroenterology|May 7, 2015
Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel diseaseRaghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, et al.
Journal of Virology|April 13, 2007
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissueRaghavan Chinnadurai, Devi Rajan, Jan Münch, et al.
AIDS (London, England)|October 18, 2005
Inhibition of HIV-1 group M and O isolates by fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Matthias T Dittmar, et al.
Biomed Research International|December 19, 2013
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseasesRaghavan Chinnadurai, Edmund K Waller, Jacques Galipeau, et al.
Oncotarget|December 2, 2017
The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cellsHolly C Lewis, Raghavan Chinnadurai, Steven E Bosinger, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Advances in Experimental Medicine and Biology|May 31, 2023
Advanced Technologies for Potency Assay MeasurementRaghavan Chinnadurai
Hepatology (Baltimore, Md.)|November 11, 2010
B7-H4 mediates inhibition of T cell responses by activated murine hepatic stellate cellsRaghavan Chinnadurai, Arash Grakoui
Stem Cells (Dayton, Ohio)|October 29, 2025
Opportunities with artificial intelligence in assessing the potency of mesenchymal stromal cellsRaghavan Chinnadurai, Anant Madabhushi
Frontiers in Immunology|May 8, 2023
Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysisRaghavan Chinnadurai, Sowmya Viswanathan, Guido Moll
AIDS (London, England)|August 17, 2005
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Frank Kirchhoff
World Journal of Gastroenterology|May 7, 2015
Challenges in animal modelling of mesenchymal stromal cell therapy for inflammatory bowel diseaseRaghavan Chinnadurai, Spencer Ng, Vijayakumar Velu, et al.
Journal of Virology|April 13, 2007
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissueRaghavan Chinnadurai, Devi Rajan, Jan Münch, et al.
AIDS (London, England)|October 18, 2005
Inhibition of HIV-1 group M and O isolates by fusion inhibitorsRaghavan Chinnadurai, Jan Münch, Matthias T Dittmar, et al.
Biomed Research International|December 19, 2013
From single nucleotide polymorphisms to constant immunosuppression: mesenchymal stem cell therapy for autoimmune diseasesRaghavan Chinnadurai, Edmund K Waller, Jacques Galipeau, et al.
Oncotarget|December 2, 2017
The IDO inhibitor 1-methyl tryptophan activates the aryl hydrocarbon receptor response in mesenchymal stromal cellsHolly C Lewis, Raghavan Chinnadurai, Steven E Bosinger, et al.
Pageof 5